Wedbush analyst David Nierengarten has reiterated an Outperform rating on Immunome (NASDAQ: IMNM), maintaining a price target of $31. This endorsement reflects continued confidence in the company's performance and market position.

The rating and price target remain unchanged, signaling a steady outlook for the stock. Investors following Immunome will note the consistency in Wedbush's assessment.

Immunome, Inc. has dosed the first patient in its Phase 1, first-in-human trial of IM-1617, an antibody-drug conjugate (ADC) designed to treat advanced solid tumors. The trial marks a significant step in the development of the company's potential first-in-class therapy, which incorporates its proprietary TOP1 inhibitor payload, HC74. The study will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of IM-1617.

The Phase 1 trial is an open-label, multicenter dose escalation and expansion study. It is expected to enroll participants with advanced solid tumors, including colorectal cancer, non-small cell lung cancer, and breast cancer. The primary focus is to determine the safety profile and recommended dose for further development.

IM-1617 is directed at an undisclosed solid tumor target and leverages Immunome's proprietary HC74 payload. The therapy aims to address unmet medical needs in oncology by targeting specific tumor types with high precision. The trial's design allows for dose escalation to identify the maximum tolerated dose while monitoring for adverse events.

The study's multicenter approach ensures diverse patient participation and robust data collection. Immunome's proprietary ADC technology combines the targeting capability of antibodies with the potency of cytotoxic payloads, offering a novel mechanism of action. The trial's outcomes will inform future clinical development strategies for IM-1617.

Key Trial Details